Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Exploitation of a Newly Characterized Metabolic-Cytoskeletal Axis for Effective Combination Therapy of Iron Restricted Anemia

Adam N Goldfarb, MD, Katie Freeman, BA, Alejandro Ariel Gru, MD, Zollie White, III, MS, Lorrie L Delehanty, BS

Blood (2019) 134 (Supplement_1): 2233.

https://doi.org/10.1182/blood-2019-129172

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

Journal Articles

Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia

Jean-Emmanuel Sarry, PhD, Christian Recher, MD PhD, Lucille Stuani, PhD, Jean-Charles Portais, PhD

Blood (2018) 132 (Supplement 1): 5238.

https://doi.org/10.1182/blood-2018-99-112523

Published: 2018

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

Charu Gupta, Michelle Maria Araujo Cruz, PhD, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Ramya Goparaju, PhD, Kerstin Görlich, Renate Schottmann, Eduard Struys, PhD, Erwin E Jansen, Felicitas Thol, MD, Arnold Ganser, MD, Michael Heuser, MD, Anuhar Chaturvedi, PhD

Blood (2018) 132 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2018-99-110159

Published: 2018

Journal Articles

An Orchestrated Balance between Mitochondria Biogenesis, Iron-Sulfur Cluster Synthesis and Cellular Iron Acquisition

Ping La, Valentina Ghiaccio, PhD, Jianbing Zhang, PhD, Stefano Rivella

Blood (2018) 132 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2018-99-112198

Published: 2018

Journal Articles

Cancer Metabolism Therapeutic Strategies: Success of Online Education in Improving Knowledge and Confidence of Hematologists/Oncologists

Patricia M Repetto, MD, Richard M. Stone, MD

Blood (2017) 130 (Supplement 1): 5622.

https://doi.org/10.1182/blood.V130.Suppl_1.5622.5622

Published: 2017

Journal Articles

Utilization of a-Ketoglutarate for Synthesis of 2-Hydroxyglutarate Oncometabolite Promotes Catabolic Flexibility, Redox Perturbation and Mitochondrial Activity That Supports Chemoresistance in IDH1 Mutant Acute Myeloid Leukemia

Lucille Stuani, PhD, Christian Recher, MD PhD, Jean-Charles Portais, PhD, Jean-Emmanuel Sarry, PhD

Blood (2017) 130 (Supplement 1): 5080.

https://doi.org/10.1182/blood.V130.Suppl_1.5080.5080

Published: 2017

Journal Articles

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

Blood (2016) 128 (22): 1073.

https://doi.org/10.1182/blood.V128.22.1073.1073

Published: 2016

Journal Articles

Isocitrate Dehydrogenase 1 Mutant Cancers Are Metabolically Vulnerable to Inhibition of Acetyl CoA Carboxylase Via a 2-Hydroxyglutarate Independent Mechanism

Daniel Thomas, MD PhD, Subarna Sinha, PhD, Steven M. Chan, MD PhD, Manhong Wu, Damoun Torabi, Gary Peltz, MD PhD, Yang Gao, David L Dill, PhD, Ravi Majeti, MD PhD

Blood (2016) 128 (22): 1054.

https://doi.org/10.1182/blood.V128.22.1054.1054

Published: 2016

Journal Articles

Aconitase: An Iron Sensing Regulator of Mitochondrial Oxidative Metabolism and Erythropoiesis

Naomi D Gunawardena, BS, Valerie Schrott, MS, Chanté Richardson, PhD, Teague Nolan Cole, BS, Catherine G Corey, BS, Yinna Wang, PhD, Sruti S Shiva, PhD, Grant C Bullock, MD PhD

Blood (2016) 128 (22): 74.

https://doi.org/10.1182/blood.V128.22.74.74

Published: 2016

Journal Articles

Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms

Remco Molenaar, M.Sc., Srinivasa Reddy Sanikommu, MD, Bhumika J. Patel, Bartlomiej Przychodzen, MSc, Cornelis J van Noorden, PhD, Tomas Radivoyevitch, PhD, Hideki Makishima, MD PhD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 1405.

https://doi.org/10.1182/blood.V126.23.1405.1405

Published: 2015

Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD

Blood (2015) 126 (23): 2509.

https://doi.org/10.1182/blood.V126.23.2509.2509

Published: 2015

Journal Articles

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

Juliana Vélez Luján, PhDCandidate, Niki Zacharias, PhD, Dinesh Rakheja, MD, Tushar D Bhagat, PhD, Jaehyuk Lee, PhD, Prasanta Dutta, PhD, Doriann Gonzalez, MDStudent, Michael Andreeff, MD PhD, Pratip K Bhattacharya, PhD, Amit Verma, M.B.,B.S., Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2559.

https://doi.org/10.1182/blood.V126.23.2559.2559

Published: 2015

NARROW

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Exploitation of a Newly Characterized Metabolic-Cytoskeletal Axis for Effective Combination Therapy of Iron Restricted Anemia

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia

Predictive Response Biomarkers for BET Inhibitors in AML

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

An Orchestrated Balance between Mitochondria Biogenesis, Iron-Sulfur Cluster Synthesis and Cellular Iron Acquisition

Cancer Metabolism Therapeutic Strategies: Success of Online Education in Improving Knowledge and Confidence of Hematologists/Oncologists

Utilization of a-Ketoglutarate for Synthesis of 2-Hydroxyglutarate Oncometabolite Promotes Catabolic Flexibility, Redox Perturbation and Mitochondrial Activity That Supports Chemoresistance in IDH1 Mutant Acute Myeloid Leukemia

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

Isocitrate Dehydrogenase 1 Mutant Cancers Are Metabolically Vulnerable to Inhibition of Acetyl CoA Carboxylase Via a 2-Hydroxyglutarate Independent Mechanism

Aconitase: An Iron Sensing Regulator of Mitochondrial Oxidative Metabolism and Erythropoiesis

Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only